SUMMARY Propranolol has been reported to diminish renal perfusion and impair sodium excretion, but the relationship of these phenomena has not been well characterized during chronic propranolol administration in hypertensive man, nor has the potential involvement of the renal kallikreinkinin system been explored. Fifteen essential hypertensive white men were treated with both placebo and oral propranolol for 1 month each, with dosage titrated for blood pressure control. Propranolol 
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sives before and after 1 month of propranolol therapy, assessing renal perfusion, renal electrolyte handling, and several potential mediators of propranolol effects on the kidney, including intravascular volume, the renal kallikrein-kinin system, the renin-angiotensinaldosterone system, and the sympathetic nervous system.
Materials and Methods

Patients
Patients were 15 white male essential hypertensives who had mean arterial pressures (MAP) (defined as diastolic blood pressure plus 1/3 pulse pressure) greater than 105 mm Hg, as outpatients. Their mean age was 52.1 ± 2.3 years, with a range of 36 to 67 years. Before the study, they were screened for secondary causes of hypertension with determinations of blood urea nitrogen (BUN) concentration and the serum concentration of sodium, potassium, chloride, and bicarbonate; hemogram; electrocardiogram; chest roentgenogram; intravenous urogram; and 24-hour urinary collection for excretion of catecholamines, metanephrines, vanillylmandelic acid, and 17 hydroxycorticosteroids. After this screening, all subjects were found to be essential hypertensives. In addition, all patients with demonstrable target organ damage from hypertension (specifically, stroke, congestive heart failure, myocardial infarction, or renal insufficiency) were excluded.
To establish a normal range for renal blood flow and urinary kallikrein excretion, we also studied 10 healthy adult white male normotensive volunteers on no medications, matched to the hypertensives for sex (male), race (white), age (mean 46.8 ± 2.4 years, p > 0.1 vs the hypertensives), and dietary sodium intake (unrestricted, > 100 mEq/24 hrs).
Each subject gave his informed, written consent, and the Human Subjects Committee of the University of California, San Diego, approved the protocol.
Procedures
In random order patients were given oral placebo for I month or oral propranolol for 1 month, at a dose individually titrated for blood pressure control (MAP < 105 mm Hg). The dose range was 80 to 320 mg/day, with median dose of 160 mg/day, and a mean ± SEM of 168.0 ± 19.6 mg/day. No other medications were taken, and the diet was unrestricted in fluid and salt.
At the end of each 1 month period, patients were admitted to the Special Diagnostic and Treatment Unit of the San Diego Veteans Administration Medical Center for a 2 day protocol evaluation. During the admission, as well as during outpatient status, the diet was unrestricted in fluid, sodium (> 100 mEq/day), and potassium (> 50 mEq/day).
Blood pressure was obtained in the supine position on admission, with a standard sphygmomanometer, and the MAP was calculated as noted above. The diastolic blood pressure was taken as the phase V Korotkoff sound (disappearance).
On the first admission day, urine was collected over 24 hours for measurement of kallikrein activity and the excretion of free catecholamines, volume, creatinine, sodium, potassium, and chloride. During collection, the urine was kept refrigerated at 4° C, and at the end of 24 hours, the volume was measured and an aliquot frozen at -80° C for later analysis.
On the morning of Day 2, blood was obtained for determination of BUN, serum creatinine, serum electrolytes, hemogram, total serum protein, supine plasma renin activity (SPRA), and upright plasma renin activity (UPRA), supine plasma aldosterone concentration, and supine and upright plasma dopamine-Bhydroxylase (DBH) activity.
Plasma volume and whole blood volume were determined utilizing both "Cr-tagged autologous erythrocytes and l25 I-albumin. The isotopes were injected intravenously and blood and plasma samples were obtained for counting at 10 and 20 minutes in the Volemetron apparatus. 14 Detailed renal hemodynamic studies were undertaken in the 15 patients. Glomerular filtration rate (GFR) was measured by the clearance of endogenous creatinine (C LT ). Renal plasma flow (RPF) was measured in the supine position from 7:00 am to 11:00 am, using the method of constant infusion of paraaminohippurate (PAH) without urine collection to determine the clearance of PAH (C PAH ). This method has proved reliable in our previous studies of renal blood flow in normotensive and hypertensive man. 16 The 10 normotensive white males underwent a hospitalization as described above, except that they were studied only once and received neither placebo nor propranolol. We report here these patients' renal blood flows and urinary kallikrein activities in order to establish comparative norms for these parameters in white normotensive males on an unrestricted sodium diet; that is, the group was matched for race, sex, age, and dietary sodium intake.
Chemical Assays
Blood for renin and aldosterone determination was drawn into chilled EDTA tubes which were kept on ice until the samples could be centrifuged and the plasma frozen at -30°C. Plasma renin activity was determined by radioimmunoassay, 17 with results in nanograms of angiotensin I generated per ml plasma per hour (ng A/ml/hr). Plasma aldosterone concentration was determined by radioimmunoassay, 18 with results expressed as picograms per ml plasma (pg/ml).
Blood for plasma dopamine-B-hydroxylase determination was drawn into chilled heparin tubes and kept on ice until the samples were centrifuged and the plasma frozen at -30°C until assay. Enzymatic activity was determined spectrophotometrically," with results expressed as international units (IU)/liter of plasma (IU/liter). where an IU is 1 /u.mole of octopamine formed from tyramine per minute at 37°C.
Urinary free catecholamines were determined by the trihydroxyindole fluorimetric method, 20 while urinary vanillylmandelic acid was assayed by the spectrophotometric method. 21 Urinary kallikrein activity was measured by enzymatic hydrolysis of radiolabelled p-tosyl arginine methylester (TAME) 22 n under our conditions for assay, pH 8.5 and 37°C, 16 ' 24 using a purified human urinary kallikrein internal standard to correct for recovery, 24 with results expressed as esterase units/24 hrs (EU/24 hrs), where an esterase unit is defined as the amount of enzyme that hydrolyzes 1 /xmole TAME/ minute at pH 8.5 and 37°C. Urinary TAME esterolytic activity correlates with kallikrein bioactivity (r = 0.95 for esterase activity versus rat blood pressure reduction) in our laboratory. 24 
Calculations
Filtration fraction was calculated as the quotient of C C/ C PAH 0-e -. GFR/RPF). Renal blood flow (RBF, in ml/min) was obtained by the formula RBF = (RPF/1-venous hematocrit). Total renal vascular resistance (RVR, in dyne-sec/cm 5 ) was computed 16 ^ as the quotient of MAP/RBF. Fractional sodium excretion was calculated, over 24 hours, as the sodium excreted divided by that filtered at the glomerulus. 26 
Statistics
Results are expressed as the mean value plus or minus the standard error of the mean. Paired t tests determined the significance of differences between subjects on placebo and propranolol, while unpaired t tests assessed the difference between normal controls and hypertensive patients on either placebo or propranolol. Correlations were performed by linear least squares regression analysis. Significance was taken to be a p value of 0.05 or less. 27 Analysis of some biochemical correlates of renal function is shown in table 4. Urinary kallikrein excretion fell by 47% during propranolol treatment (from 9.0 ± 2.7 to 4.8 ± 1.3 EU/24 hrs, p < 0.04). Reference to the normotensive control group (table 3, fig. 1 ) shows that urinary kallikrein excretion was diminished by 55% in the hypertensives vs normotensives (20.0 ± 3.8 vs 9.0 ± 2.7 EU/24 hrs, p < 0.03), and this diminution, too, was enhanced by propranolol (down to4.8 ± 1.3 EU/24 hrs, p<0.04 vs placebo, p< 0.01 vs normotensives).
Plasma renin activity was unchanged in the supine position (p > 0.1) but declined in the upright position on propranolol, from 1.44 ± 0.36 to 0.53 ± O.I7ng Al/ml/hr (p < 0.05, table 4). Plasma aldosterone concentration was diminished by propranolol (from 68.4 ± 9.6 to 61.4 ± 16.1 pg/ml, p < 0.02).
All biochemical indices of sympathetic nervous system activity were unchanged by propranolol (all p > 0.1, table 4).
Urinary excretion of volume, creatinine, and electrolytes is considered in table 5. The excretion of volume and creatinine was unchanged from placebo to propranolol phase (p > 0.1), as was the total 24-hour excretion of sodium, potassium, and chloride (all p > 0.1, NS), in spite of the diminution of GFR (table 2) . However, the fractional excretion of sodium rose on propranolol (from 0.75 ± 0.09 to 0.96 ± 0.06%, p< 0.05), while the urinary sodium/potassium ratio also increased on propranolol (from 2.41 ± 0.33 up to 3.12 ± 0.30, p < 0.01). Change in fractional sodium excretion did not correlate with change in plasma aldosterone concentration (r = -0.05) but did correlate with change in urinary sodium/potassium ratio (r = 0.82, p < 0.01, fig. 2 ).
Results
The hypertensives had a fall in blood pressure on propranolol (p < 0.01) into the normotensive range (table I) , with an associated fall in heart rate (p < 0.01), but no change in weight, plasma volume, or whole blood volume (all p > 0.1). Blood urea nitrogen and serum creatinine were unchanged on propranolol, as were serum sodium, potassium, chloride, total protein, and hematocrit (all p > 0.1).
Assessment of renal hemodynamics, however, revealed that propranolol treatment produced significant decrements in GFR, RPF, and RBF(allp < 0.05, table 2), without associated changes in filtration fraction or total renovascular resistance (allp > 0.1). The magnitude of the decline in GFR was 12.1%, while that of renal plasma flow was 14.5%, and that of renal blood flow, 15.8%.
When renal perfusion in the hypertensive group was compared to that in the normotensive control group (table 3) , renal blood flow was diminished by 21% in the hypertensives vs normotensives (1096 ± 84 vs 1386 ± 117 ml/min, p < 0.05), and this diminution was compounded by propranolol (to 923 ± 38 ml/min, p < 0.01 vs placebo, p < 0.01 vs normotensives). 
FIGURE 2. Change in fractional sodium excretion as a function of change in urinary sodiumlpotassium ratio, going from placebo to propranolol. Each point is an individual subject. The two parameters increased in parallel (r = 0.82, p 0.01).
To investigate change in renal blood flow from placebo to propranolol, the change was correlated (table 6) with several pretreatment variables (predictors of change) and change in several other variables (covariants). Change in renal blood flow correlated inversely with pretreatment renal blood flow (r = -0 . 9 1 , p < 0.01; fig. 3 ) and pretreatment urinary catecholamine excretion (r = -0.64, p < 0.01), directly with pretreatment renal vascular resistance (r = 0.85, p < table 6 ) or change in several other parameters (propranolol dose, MAP, heart rate, GFR, urinary electrolyte excretion, plasma renin activity, or plasma aldosterone concentration). Likewise, to investigate change in kallikrein excretion from placebo to propranolol, the change was cor-
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*p < 0.01 for correlation coefficient. In each case, the dependent variable in the correlation is change in renal blood flow. related (table 7) with several pretreatment variables (predictors of change) and change in several other variables (co-variants). Change in kallikrein excretion correlated inversely with pretreatment kallikrein excretion (r = -0 . 8 7 , p < 0.01; fig. 6 ), but there were no other significant predictors or covariants identified (age, propranolol dose, MAP, heart rate, GFR, RBF, RVR, plasma volume, whole blood volume, urinary electroyte excretion, plasma renin activity, plasma aldosterone concentration, or plasma dopamine-B-hydroxylase activity).
Discussion
Propranolol lowered blood pressure in these hypertensive subjects without any appreciable change in the usual serum indices of renal function (BUN and creatinine), but declines in GFR (12%), RPF (15%), and RBF (16%) were noted, in accordance with previous observations. 5 
What is the mechanism for the fall in renal blood flow? Prior studies have suggested several explanations, including: impaired renal perfusion autoregulation, 28 unopposed alpha vasoconstriction in the renal bed after beta blockade, 29 a direct alpha agonist effect of propranolol in renal vessels , J0 and a renal blood flow decline in parallel with a systemic blood flow (cardiac output) decline. 310 -11 Our data suggest a failure of renal perfusion autoregulation, since the renal perfusion decrement correlated with a renal resistance increment (fig. 5) ; the normal response of the kidney to reduced perfusion pressure is a decrease in RVR. 32 The renal perfusion decrement in our subjects was heterogenous, occurring most prominently in those with a relatively "normal" renal vascular tree, i.e., those with the highest RBFs and lowest RVRs (figs. 3 and 4); those with evidence of the most nephrosclerosis (low RBF, high RVR) had little if any decline in RBF on propranolol. Perhaps those with nephrosclerosis had a relatively inelastic renal bed, impervious to further vasoconstriction. In addition, the inverse correlation of RBF decrement with basal urinary catecholamine excretion, coupled with the direct correlation between basal catecholamine excretion and basal renal blood flow, suggests that the fall in renal perfusion is greatest in those subjects with the highest endogenous sympathetic tone; one might expect a greater degree of unopposed alpha mediated renal vasoconstriction after beta blockade in such subjects, even without change in endogenous sympathetic activity. This heterogeneity of renal blood flow response may help explain conflicting results in other studies of beta blocker effects on renal function,' and may explain the especially pronounced effects of propranolol upon renal perfusion in normotensive, healthy subjects. 6 Why did kallikrein diminish after propranolol? Potential mechanisms include diminished mineralocorticoid activity 1 ' and a direct linkage of a renal beta receptor to kallikrein excretion." Mineralocorticoid activity was diminished, but change in plasma aldosterone concentration or urinary sodium/potassium ratio did not correlate with the kallikrein decrement; nor was the kallikrein fall dose dependent, weighing against direct beta blockade as the explanation (table 7) . In fact, the only significant predictor of a marked fall in kallikrein excretion was a relatively high pretreatment kallikrein excretion ( fig. 6) .
While there was a progressive decrease in both RBF and kallikrein excretion in the groups normals-^hyper-tensives on placebo-*hypertensives on propranolol (tables 2-4; fig. 1 ), there was no significant correlation (/• = -0.16) between RBF decrement and kallikrein decrement after propranolol, casting some doubt on kallikrein decrement as a mechanism for RBF decrement. Indeed, some would suggest that diminished kallikrein excretion could be secondary to the decline in RBF. 14 Some studies suggest that propranolol is antinatriuretic. 9 -11 •" We found no change in plasma volume, blood volume, weight, or overall sodium excretion on propranolol, however, consistent with other studies where plasma volume has not been expanded by longterm use of the drug.- 16 "- 18 Sodium excretion remained unimpaired even in the face of diminished GFR; the quantitative expression for this phenomenon is the increase in the fractional sodium excretion, or that fraction of filtered sodium which is excreted, from 0.75% ± 0.09% up to 0.96% ± 0.06% (p < 0.05, table 4). Preservation of sodium homeostasis and excretion via an increase in fractional sodium excretion as GFR declines, is reminiscent of the usual adaptive renal response to nephron loss. 40 Correlation of fractional sodium excretion enhancement with the increase in urinary sodium/potassium ratio (r = 0.82, fig. 2 ), coupled with decreased plasma aldosterone concentration, suggests that diminished mineralocorticoid activity lead to enhanced excretion of filtered sodium.
Was there a role for renal kallikrein in this change in renal sodium handling? Some studies suggest that the renal kallikrein-kinin system is natriuretic 41 -42 while others suggest that it is antinatriuretic in action. 41 We found an increase in fractional sodium excretion (that is. a natriuretic effect) in association with a decrease in kallikrein excretion on propranolol, suggesting, perhaps, that kallikrein was antinatriuretic in this setting. However, change in kallikrein excretion did not correlate with either change in fractional sodium excretion or change in urinary sodium/potassium ratio (table 7) , weighing against a prominent kallikrein mediation of the electrolyte changes noted.
In summary, hypertensives given propranolol had a decrease in GFR, RPF, RBF, plasma aldosterone concentration, and urinary kallikrein excretion. Decrement in kallikrein excretion did not correlate with RBF fall. Sodium homeostasis was maintained by an enhanced fractional sodium excretion, best explained by diminished mineralocorticoid activity with an increase in the urinary sodium/potassium ratio. No correlation was found between kallikrein change and electrolyte excretion changes.
D T O'Connor and R A Preston
beta blockade with propranolol in hypertension.
Urinary kallikrein activity, renal hemodynamics, and electrolyte handling during chronic
